RecruitingNCT02803970
KOrean Borderline Ovarian Tumor (KOBOT) Registry
Establishing the Registry of Korean Patients With Borderline Ovarian Tumors
Sponsor
Kangbuk Samsung Hospital
Enrollment
3,000 participants
Start Date
Dec 1, 1994
Study Type
OBSERVATIONAL
Conditions
Summary
The aim of this study is to collect data on Korean patients with borderline ovarian tumors.
Eligibility
Sex: FEMALE
Inclusion Criteria2
- Patients with borderline ovarian tumors (BOTs) diagnosed, treated, and followed between November 1994 and February 2015 at institutions where placed in the Republic of Korea.
- All patients undergoing gynecologic surgery for BOTs at institutions where placed in the Republic of Korea since March, 2015
Exclusion Criteria1
- Patients who did not receive primary treatment or follow-up for at least 6 months at each institution were excluded from analysis
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02803970
Related Trials
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632154 locations
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
NCT073185585 locations
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
NCT07213804251 locations
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT0721379127 locations
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
NCT0489570950 locations